View Clinical Trial (Medical Research Study)
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. - NCT00855465-02114(Clinical Trial 275646)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Boston |
|
State:
|
|
MA |
| Zip Code: |
|
02114 |
| Conditions: |
|
Pulmonary Hypertension |
| Purpose: |
|
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521,
given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension
(CTEPH).
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Male and female patients with CTEPH either inoperable or with persistent or recurrent PH
after surgery.
Exclusion Criteria:
- All types of pulmonary hypertension except subtypes 4.1 and 4.2 of the Venice
Clinical Classification of Pulmonary Hypertension. |
|
|
|
| Study is available at: |
|
Boston, MA 02114
United States
Primary Contact:
Bayer Clinical Trials Contact
Email: clinical-trials-contact@bayerhealthcare.com |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 23, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|